Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05898399 | Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) | recruiting | Phase 1 / Phase 2 | 181 | Artios Pharma LtdINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT06150183 | Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors | active not recruiting | Phase 1 | 41 | BioNTech SEINDUSTRY | 6 | Sep 15, 2026 | clinicaltrials |
| NCT06244485 |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors |
| active not recruiting |
| Phase 1 |
| 210 |
| Daiichi SankyoINDUSTRY |
| 4 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT06303167 | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) | active not recruiting | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06308822 | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07165132 | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | recruiting | Phase 1 | 104 | RayzeBio, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 280 | Incyte CorporationINDUSTRY | 5 | Sep 15, 2026 | clinicaltrials |
| NCT07532018 | DXP-106 in Solid Tumor Patients.(DXP-106) | recruiting | Phase 1 | 54 | Singlomics Biopharmaceuticals Zhuhai Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | not yet recruiting | Phase 1 / Phase 2 | 77 | Children's Oncology GroupNETWORK | 0 | Sep 15, 2026 | clinicaltrials |
| NCT01012817 | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | active not recruiting | Phase 1 / Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02464696 | Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure | recruiting | N/A | 256 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04084067 | Indocyanine Green (ICG) Guided Tumor Resection | completed | Phase 1 | 215 | St. Jude Children's Research HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | suspended | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04984551 | Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia | recruiting | Phase 2 | 312 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05067283 | A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)(KANDLELIT-001) | recruiting | Phase 1 | 830 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Sep 14, 2026 | clinicaltrials |
| NCT05262400 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 235 | PfizerINDUSTRY | 9 | Sep 14, 2026 | clinicaltrials |
| NCT05430373 | GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors | recruiting | Phase 1 | 31 | Grit BiotechnologyINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05691608 | MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2(MAPPYACTS2) | recruiting | N/A | 1,800 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06134960 | NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor | recruiting | Phase 1 | 12 | Peking UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06192875 | A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study) | recruiting | — | 10,000 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT06589596 | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 525 | BeOne MedicinesINDUSTRY | 11 | Sep 14, 2026 | clinicaltrials |
| NCT06596473 | A Study of BG-C477 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 310 | BeOne MedicinesINDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT07818486 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818798 | Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors(LARGE-Proton) | not yet recruiting | — | 60 | Peking University First HospitalOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT01375829 | Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02079740 | Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 170 | Hoffmann-La RocheINDUSTRY | 9 | Sep 11, 2026 | clinicaltrials |
| NCT04739696 | Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.(eCare) | active not recruiting | N/A | 538 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT04875286 | Patient Reported Symptom Control With THC or CBD Use | active not recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04905082 | HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics | active not recruiting | N/A | 465 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe) | active not recruiting | Phase 1 / Phase 2 | 320 | Ascendis Pharma Oncology Division A/SINDUSTRY | 10 | Sep 11, 2026 | clinicaltrials |
| NCT05095948 | Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center | not yet recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05432232 | The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy(CAIN) | completed | N/A | 20 | HistoSonics, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06046742 | A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 12 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06292845 | Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents(SprayDye) | recruiting | N/A | 200 | Erasmus Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06598800 | Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 153 | BeOne MedicinesINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT07225088 | DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer | recruiting | N/A | 125 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07278739 | Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams | recruiting | N/A | 1,020 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07586943 | SKB118 Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 530 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07719920 | A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 99 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07729384 | Strengthening Teen Brain Resilience Using Music Intervention to Improve Radiation Induced Cognitive Decline for Adolescents Undergoing Radiation Therapy for Cancer Treatment | not yet recruiting | N/A | 30 | Mayo ClinicOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07746141 | A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations | recruiting | Phase 1 | 100 | BeOne MedicinesINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01364051 | Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies | active not recruiting | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials